Maternal and fetal antibrain antibodies in development and disease

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Recent evidence has emerged indicating that the maternal immune response can have a substantial deleterious impact on prenatal development (Croen et al., [2008]: Biol Psychiatry 64:583-588). The maternal immune response is largely sequestered from the fetus. Maternal antibodies, specifically immunoglobulin G (IgG), are passed to the fetus to provide passive immunity throughout much of pregnancy. However, both protective and pathogenic autoantibodies have equal access to the fetus (Goines and Van de Water [2010]: Curr Opin Neurol 23:111-117). If the mother has an underlying autoimmune disease or has reactivity to fetal antigens, autoantibodies produced before or during pregnancy can target tissues in the developing fetus. One such tissue is the fetal brain. The blood brainbarrier (BBB) is developing during the fetal period allowing maternal antibodies to have direct access to the brain during gestation (Diamond et al. [2009]: Nat Rev Immunol; Braunschweig et al. [2011]; Neurotoxicology 29:226-231). It has been proposed that brain injury by circulating brain-specific maternal autoantibodies might underlie multiple congenital, developmental disorders (Lee et al. [2009]: Nat Med 15:91-96). In this review, we will discuss the current state of research in the area of maternal autoantibodies and the development of autism.

Original languageEnglish (US)
Pages (from-to)1327-1334
Number of pages8
JournalDevelopmental Neurobiology
Volume72
Issue number10
DOIs
StatePublished - Oct 2012

Fingerprint

Mothers
Fetus
Autoantibodies
Antibodies
Pregnancy
Brain
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Autistic Disorder
Brain Injuries
Autoimmune Diseases
Psychiatry
Immunity
Immunoglobulin G
Antigens
Water
Research

Keywords

  • Anti-brain antibodies
  • Autism spectrum disorders
  • Maternal antibodies
  • Neuronal development

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience

Cite this

Maternal and fetal antibrain antibodies in development and disease. / Fox, Elizabeth; Amaral, David G; Van de Water, Judith A.

In: Developmental Neurobiology, Vol. 72, No. 10, 10.2012, p. 1327-1334.

Research output: Contribution to journalArticle

@article{c99d2271d6a14b53b170ebc5271b0c57,
title = "Maternal and fetal antibrain antibodies in development and disease",
abstract = "Recent evidence has emerged indicating that the maternal immune response can have a substantial deleterious impact on prenatal development (Croen et al., [2008]: Biol Psychiatry 64:583-588). The maternal immune response is largely sequestered from the fetus. Maternal antibodies, specifically immunoglobulin G (IgG), are passed to the fetus to provide passive immunity throughout much of pregnancy. However, both protective and pathogenic autoantibodies have equal access to the fetus (Goines and Van de Water [2010]: Curr Opin Neurol 23:111-117). If the mother has an underlying autoimmune disease or has reactivity to fetal antigens, autoantibodies produced before or during pregnancy can target tissues in the developing fetus. One such tissue is the fetal brain. The blood brainbarrier (BBB) is developing during the fetal period allowing maternal antibodies to have direct access to the brain during gestation (Diamond et al. [2009]: Nat Rev Immunol; Braunschweig et al. [2011]; Neurotoxicology 29:226-231). It has been proposed that brain injury by circulating brain-specific maternal autoantibodies might underlie multiple congenital, developmental disorders (Lee et al. [2009]: Nat Med 15:91-96). In this review, we will discuss the current state of research in the area of maternal autoantibodies and the development of autism.",
keywords = "Anti-brain antibodies, Autism spectrum disorders, Maternal antibodies, Neuronal development",
author = "Elizabeth Fox and Amaral, {David G} and {Van de Water}, {Judith A}",
year = "2012",
month = "10",
doi = "10.1002/dneu.22052",
language = "English (US)",
volume = "72",
pages = "1327--1334",
journal = "Developmental Neurobiology",
issn = "1932-8451",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Maternal and fetal antibrain antibodies in development and disease

AU - Fox, Elizabeth

AU - Amaral, David G

AU - Van de Water, Judith A

PY - 2012/10

Y1 - 2012/10

N2 - Recent evidence has emerged indicating that the maternal immune response can have a substantial deleterious impact on prenatal development (Croen et al., [2008]: Biol Psychiatry 64:583-588). The maternal immune response is largely sequestered from the fetus. Maternal antibodies, specifically immunoglobulin G (IgG), are passed to the fetus to provide passive immunity throughout much of pregnancy. However, both protective and pathogenic autoantibodies have equal access to the fetus (Goines and Van de Water [2010]: Curr Opin Neurol 23:111-117). If the mother has an underlying autoimmune disease or has reactivity to fetal antigens, autoantibodies produced before or during pregnancy can target tissues in the developing fetus. One such tissue is the fetal brain. The blood brainbarrier (BBB) is developing during the fetal period allowing maternal antibodies to have direct access to the brain during gestation (Diamond et al. [2009]: Nat Rev Immunol; Braunschweig et al. [2011]; Neurotoxicology 29:226-231). It has been proposed that brain injury by circulating brain-specific maternal autoantibodies might underlie multiple congenital, developmental disorders (Lee et al. [2009]: Nat Med 15:91-96). In this review, we will discuss the current state of research in the area of maternal autoantibodies and the development of autism.

AB - Recent evidence has emerged indicating that the maternal immune response can have a substantial deleterious impact on prenatal development (Croen et al., [2008]: Biol Psychiatry 64:583-588). The maternal immune response is largely sequestered from the fetus. Maternal antibodies, specifically immunoglobulin G (IgG), are passed to the fetus to provide passive immunity throughout much of pregnancy. However, both protective and pathogenic autoantibodies have equal access to the fetus (Goines and Van de Water [2010]: Curr Opin Neurol 23:111-117). If the mother has an underlying autoimmune disease or has reactivity to fetal antigens, autoantibodies produced before or during pregnancy can target tissues in the developing fetus. One such tissue is the fetal brain. The blood brainbarrier (BBB) is developing during the fetal period allowing maternal antibodies to have direct access to the brain during gestation (Diamond et al. [2009]: Nat Rev Immunol; Braunschweig et al. [2011]; Neurotoxicology 29:226-231). It has been proposed that brain injury by circulating brain-specific maternal autoantibodies might underlie multiple congenital, developmental disorders (Lee et al. [2009]: Nat Med 15:91-96). In this review, we will discuss the current state of research in the area of maternal autoantibodies and the development of autism.

KW - Anti-brain antibodies

KW - Autism spectrum disorders

KW - Maternal antibodies

KW - Neuronal development

UR - http://www.scopus.com/inward/record.url?scp=84865835793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865835793&partnerID=8YFLogxK

U2 - 10.1002/dneu.22052

DO - 10.1002/dneu.22052

M3 - Article

VL - 72

SP - 1327

EP - 1334

JO - Developmental Neurobiology

JF - Developmental Neurobiology

SN - 1932-8451

IS - 10

ER -